August 19, 2020 -- A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal antibody (mAb) and natural killer (NK) cells as a treatment for COVID-19. The efforts are spearheaded by Harbour BioMed and expand on the company's work in using mAb against SARS-CoV-2.
Additional collaborators include Utrecht University, Erasmus Medical Center, Viroclinics, and Kiadis Pharma. The collaboration will explore the synergies between mAb and NK cells in eliminating SARS-CoV-2 and virally infected cells.
The new product will utilize Kiadis' K-NK cell therapy platform to address the severe lack of functional NK cells in COVID-19 patients. K-NK-Id101 cells potentially have antiviral activity without exacerbating inflammation. The cells can be manufactured at a large scale and frozen down for storage, making global distribution easier.
The fully human, nonblocking antibody, 49F1, targets a conserved region of the SARS-CoV-2 spike protein and binds to both SARS-CoV-2 and SARS-CoV in vitro.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
